Stay informed with the latest headlines
BofA Securities analyst Peter T. Galbo initiated coverage on Primo Brands Corporation (NYSE:PRMB), with a price forecast of $42.Galbo notes that Primo Brands stock is expected to appreciate over the next 12 months as the company realizes cost synergies, targeting $300 million in EBITDA by 2026.If valuation multiples stay steady, this should support growth in […]
Read More
SoFi Technologies Inc (NASDAQ:SOFI) stock price gained Tuesday after it reported its first-quarter 2025 earnings on Tuesday. Here’s a look at the key metrics from the quarter.The company reported quarterly adjusted sales of $770.72 million, beating analyst estimates of $739.04 million. The company reported quarterly adjusted earnings of 6 cents per share, beating analyst estimates […]
Read More
Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform.Under the multi-year collaboration agreement, Guardant and Pfizer aim to:Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies.Evaluate the clinical utility […]
Read More
JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s (NASDAQ:RARE) setrusumab program in osteogenesis imperfecta (OI).In a fourth-quarter 2024 press release, the company said patients continue dosing in the Phase 3 Orbit and Cosmic trials, which evaluate setrusumab in pediatric and young adult patients with OI.The randomized, placebo-controlled Phase 3 portion of the Orbit […]
Read More
Goldman Sachs analyst Noah Poponak expressed views on GE Aerospace‘s (NYSE:GE) fourth-quarter FY24 results.Today, the company reported fourth-quarter adjusted revenue growth of 16% year-over-year to $9.879 billion and GAAP revenue of $10.812 billion. The analyst consensus was $9.604 billion.Adjusted EPS for the quarter was $1.32 (+103% Y/Y), beating the consensus of $1.04.GE Aerospace expects FY25 […]
Read More
On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, […]
Read More